Pharma is hopeful about Trump’s second term — here’s what to expect for drugmakers

CNBC
Written by St. Paul Corner Drug (SPCD)

Pharmaceutical companies appear to be hopeful about their growth under a Trump administration, after former President Joe Biden took a hardline stance on the industry for the last four years.

Read the article here
St. Paul Corner Drug (SPCD)
Previous

Congress Can't Wait—Reform Pharmacy Benefit Managers and Deliver Lower-Cost Drugs for Patients | Opinion
Next

New AI tool counters health insurance denials decided by automated algorithms